Market Overview

RBC Looks For Post-Approval Data On MannKind

Share:
Related MNKD
After SunEdison, Twitter Users See Valeant Filing Bankruptcy Next…Not SandRidge Or Another Solar Player
Why Goldman Is Still Selling Mannkind
Oramed's Pending Oral Insulin Would Trounce Efforts Of Global Diabetes Titans (Seeking Alpha)

Shares of MannKind (NASDAQ: MNKD) have traded up as much as 11 percent Monday, following Friday's announcement by the company that AFREZZA has received FDA approval.

In response to the announcement, RBC Capital released a note stating that the next key catalysts the firm sees are post-approval data and a partnership, which the firm views as "likely."

Shares of Mannking are currently trading at $11.01, up 10.1 percent.

Posted-In: RBC CapitalAnalyst Color News FDA

 

Related Articles (MNKD)

View Comments and Join the Discussion!